Analysts at SunTrust Robinson Reconfirmed their “Buy” rating for Catalyst Pharma (CPRX) with $5.0 PT; Spectranetics (SPNC) Shorts Increased By 1.17%

September 1, 2017 - By Marguerite Chambers

Among 4 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $600 highest and $4 lowest target. $5.19’s average target is 92.22% above currents $2.7 stock price. Catalyst Pharmaceuticals had 7 analyst reports since April 26, 2016 according to SRatingsIntel. As per Wednesday, August 30, the company rating was maintained by Roth Capital. H.C. Wainwright maintained Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) on Friday, August 11 with “Buy” rating. The firm has “Neutral” rating by Piper Jaffray given on Tuesday, April 26. Piper Jaffray upgraded the shares of CPRX in report on Wednesday, October 5 to “Overweight” rating. The rating was upgraded by PiperJaffray to “Overweight” on Wednesday, October 5. The firm has “Buy” rating by Piper Jaffray given on Monday, August 7. The rating was maintained by Roth Capital with “Buy” on Thursday, August 10.

Spectranetics Corporation (NASDAQ:SPNC) had an increase of 1.17% in short interest. SPNC’s SI was 4.01 million shares in September as released by FINRA. Its up 1.17% from 3.97M shares previously. With 965,200 avg volume, 4 days are for Spectranetics Corporation (NASDAQ:SPNC)’s short sellers to cover SPNC’s short positions. The SI to Spectranetics Corporation’s float is 9.95%. It closed at $38.45 lastly. It is down 67.37% since September 1, 2016 and is uptrending. It has outperformed by 50.67% the S&P500.

About 322,060 shares traded. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has risen 267.48% since September 1, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $228.29 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.

Investors sentiment increased to 2.22 in 2016 Q4. Its up 1.01, from 1.21 in 2016Q3. It is positive, as 6 investors sold Catalyst Pharmaceuticals Inc shares while 12 reduced holdings. 9 funds opened positions while 8 raised stakes. 23.81 million shares or 1.65% more from 23.42 million shares in 2016Q3 were reported. 11,603 are owned by Two Sigma Securities Ltd. 8,097 were accumulated by Tower Research Llc (Trc). 21,109 are owned by Hbk Sorce Advisory Limited Liability Corporation. Venbio Select Advisor Limited reported 1.14M shares. Moreover, Creative Planning has 0% invested in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Point72 Asset Mgmt Lp has 2.27 million shares. Vantage Advsr Ltd owns 0% invested in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) for 3,000 shares. Manufacturers Life Insur The reported 3,218 shares. The California-based California Employees Retirement has invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Bankshares Of Mellon reported 0% stake. Weiss Multi has invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Agran Libbie holds 0.01% or 44,000 shares. 756,311 were reported by Kingdon Cap Mngmt Lc. 589,883 were reported by Tanaka Cap Mgmt Inc. Kennedy Capital Mgmt Inc, Missouri-based fund reported 233,171 shares.

Investors sentiment increased to 1.39 in Q4 2016. Its up 0.37, from 1.02 in 2016Q3. It increased, as 19 investors sold Spectranetics Corp shares while 50 reduced holdings. 23 funds opened positions while 37 raised stakes. 38.67 million shares or 1.26% more from 38.19 million shares in 2016Q3 were reported. Blackrock Inv Mgmt Ltd Liability Corp holds 159,857 shares. Blackrock Institutional Na accumulated 1.16 million shares. Engineers Gate Manager Ltd Partnership, a New York-based fund reported 34,696 shares. California Employees Retirement System has 0% invested in Spectranetics Corp (NASDAQ:SPNC). Acuta Prns Lc has 0.25% invested in Spectranetics Corp (NASDAQ:SPNC) for 27,500 shares. Loomis Sayles & Commerce Limited Partnership has 0.04% invested in Spectranetics Corp (NASDAQ:SPNC). Dafna Capital Lc invested in 1.41% or 65,496 shares. Redmile Group Ltd Liability holds 187,627 shares. 48,661 were accumulated by Parametric Port Assocs Llc. Oak Ridge Ltd Liability Company has invested 1.78% in Spectranetics Corp (NASDAQ:SPNC). Franklin Resources owns 2.10 million shares. Legal And General Gp Public Limited Co has invested 0% in Spectranetics Corp (NASDAQ:SPNC). Arrowpoint Asset Management Ltd Com invested in 2.60 million shares or 1.01% of the stock. Jpmorgan Chase accumulated 17,363 shares. Bamco Ny holds 1.54M shares.

Among 12 analysts covering Spectranetics (NASDAQ:SPNC), 4 have Buy rating, 0 Sell and 8 Hold. Therefore 33% are positive. Spectranetics had 33 analyst reports since July 27, 2015 according to SRatingsIntel. The company was downgraded on Friday, August 4 by Needham. On Friday, August 4 the stock rating was downgraded by Guggenheim to “Neutral”. The company was maintained on Monday, July 24 by RBC Capital Markets. The stock has “Hold” rating by Stifel Nicolaus on Friday, August 4. The rating was maintained by Stifel Nicolaus on Friday, February 26 with “Buy”. As per Tuesday, July 25, the company rating was downgraded by Raymond James. The firm has “Strong Buy” rating given on Friday, July 29 by Needham. The firm has “Strong Buy” rating by Needham given on Friday, October 23. The stock of Spectranetics Corp (NASDAQ:SPNC) has “Strong Buy” rating given on Friday, February 26 by Needham. Canaccord Genuity maintained Spectranetics Corp (NASDAQ:SPNC) rating on Tuesday, June 27. Canaccord Genuity has “Buy” rating and $3700 target.